Desjardins Global Asset Management Inc. Bei Gene, Ltd. Transaction History

Desjardins Global Asset Management Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	BUY	$178.3 - $266.78 $59,552 - $89,104	334 Added 23.99%	1,726 $307,000
Q1 2023 May 01, 2023	SELL	$215.53 - $274.5 $54,529 - $69,448	-253 Reduced 15.38%	1,392 $300,000
Q4 2022 Feb 08, 2023	BUY	$125.51 - $229.3 $26,482 - $48,382	211 Added 14.71%	1,645 $361,000
Q3 2022 Oct 26, 2022	SELL	$131.8 - $202.24 $11,730 - $17,999	-89 Reduced 5.84%	1,434 $193,000
Q2 2022 Aug 10, 2022	BUY	$121.11 - $216.05 $12,958 - $23,117	107 Added 7.56%	1,523 $246,000
Q1 2022 May 12, 2022	SELL	$146.52 - $269.56 $4,981 - $9,165	-34 Reduced 2.34%	1,416 $267,000
Q4 2021 Jan 31, 2022	BUY	$248.56 - $389.34 $360,412 - $564,543	1,450 New	1,450 $392,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Desjardins Global Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Desjardins Global Asset Management Inc. with notifications on news.